Ribonucleotide reductase: Target therapy for human disease

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 6, 2005, Pages 659-673

  Gallicchio, Vincent S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cancer; Didox; Hydroxyurea; Ribonucleotide reductase inhibitor; Trimidox; Viral infection; Virostatic agent

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; ABACAVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BENZOHYDROXAMIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DIDANOSINE; DOXORUBICIN; ENZYME INHIBITOR; HYDROXYLAMINE; HYDROXYUREA; INDINAVIR; PHENOL DERIVATIVE; PROTEIN P53; QUERCETIN; RESVERATROL; RIBONUCLEOTIDE REDUCTASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BIOCHEMISTRY; BONE MARROW SUPPRESSION; BREAST CANCER; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; NONHUMAN; PARASITOSIS; PATENT; PROTEIN TARGETING; REVIEW; TOXICITY TESTING; VIRUS REPLICATION;

EID: 21244443856     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.6.659     Document Type: Review

References (114)

1. KOLBERG M, STRAND KR, GRAFF P et al.: Structure, function, and mechanism of ribonucleotide redctase. Biochemica Biophys Acta (2004) 1699:1-34.
2. ELLEDGE SJ, ZHOU Z, ALLEN JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci. (1992) 17:119-123.
3. ELFORD HL, FREESE M, PASSAMIANI E et al.: Ribonucleotide reductase and cell proliferation. J. Biol. Chem. (1970) 245:5228-5233.
4. ELFORD HL: Functional regulation of mammalian ribonucleotide reductase. (1972) Adv. Enz. Reg. 10:19-38.
5. WEBER G: Enzymology of cancer cells. N. Engl. J. Med. (1977) 296:486-493.
6. STRYER L: Biochemistry, 5th Edition. Freeman & Company, NY, USA (2004).
7. REICHARD P, EHRENBERG A: Ribonucleotide reductase - a radical enzyme. Science (1983) 221:514-519.
8. BJORKLUND S, SKOG S, TRIBUKAIT B et al.: S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry (1990) 29:5452-5458.
9. REICHARD P: From RNA to DNA, why so many ribonucleotide reductases? Science (1993) 260:1773-1777.
10. EKLUND H, UHLIN U, FARNEGARDH M et al.: Structure and function of the radical enzyme ribonucleotide reductase. Prog. Biophys. Mol. Biol. (2001) 77:177-268.
11. FONTECAVE M, NORDLUND P, EKLUND H et al.: The redox centers of ribonucleotide reductase of Escherichia coli. Adv. Enzymol. (1992) 65:147-183.
12. NORDLUND P, EKLUND H: Structure and function of the Escherichia coli ribonucleotide reductase protein R2. J. Mol. Biol. (1993) 232:123-164.
13. THELANDER L, GRASLUND A: Ribonucleotide reductase in mammalian systems. In: Metal Ions in Biological Systems. Sigel HA (Ed.), Marcel-Dekker, Inc., NY, USA (1993) 30:109-129.
14. LARSSON A, SJOBERG BM: Identification of the stable free radical tyrosine residue in ribonucleotide reductase. EMBO J. (1986) 5:2037-2040.
15. SAHLIN M, SJOBERG BM, BACKES G et al.: Activation of the iron-containing R2 protein of ribonucleotide reductase by hydrogen peroxide. Biochem. Biophys. Res. Common. (1990) 167:813-818.
16. HOLMGREN A: Thioredoxin and glutaredoxin systems. J. Biol. Chem. (1989) 264:13963-13966.
17. ELIASSON R, PONTIS E, JORDAN A et al.: Altosteric regulation of the third ribonucleotide reductase (NrdEF enzyme) from enterobacteriaceae. J. Biol. Chem. (1996) 271:26582-26587.
18. JORDON A, PONTIS E, ASLUND F et al.: The ribonucleotide reductase system of Lactococcus lactis - characterization of an nrdEF enzyme and a new electron transport procein. J. Biol. Chem. (1996) 271:8779-8785.
19. YANG FD, LU GZ, RUBIN H: Isolation of ribonucleotide reductase from Mycobacterium tuberculosis and cloning, expression, and purification of the large subunit. J Bacteriol. (1994) 176:6738-6743.
20. SCOTTI C, VALBUZZI A, PEREGO M et al.: The Bacillus subtilis genes for ribonucleotide reductase are similar to the genes for the second class I NrdE/NrdF enzymes of Enterobacteriaceae. Microbiol. UK (1996) 142:2995-3004.
21. FRASER CM, VENTER JC: The minimal gene complement of Mycoplasma genitalium. Science (1995) 270:397-403.
22. JORDAN A, GILBERT I, BARBE J: Two different operons for the same function: comparison of the Salmonella typhimurium nrdAb and nrdAF genes. Gene (1995) 167:75-79.
23. JORDAN A, ARAGALL E, GILBERT I et al.: Promotor identification and expression analysis of Salmonella typhimurimum and Escherichia coli nrdEF operons encoding one of two class I ribonucleotide reductases present in both bacteria. Mol. Microbiol. (1996) 19:777-790.
24. BOOKERS, LICHT S, BRODERICK J et al.: Coenzyme B-12-dependent ribonucleotide reductase: evidence for the participation of five cysteine residues in ribonucleotide reaction. Biochemistry (1994) 33:12676-12685.
25. STUBBE JA: Ribonucleotide reductases. Adv. Enzymol. (1990) 63:349-419.
26. RIERA J, ROBB FT, WEISS R et al.: Ribonucleotide reductase in the archeon Pyrococcus furiosus: a critical enzyme in the evolution of the DNA genomes? Proc. Soc. Natl. Acad. Sci. USA (1997) 94:514-519.
27. TAUER A, BENNER SA: The B-12 dependent ribonucleotide reductase in mammalian systems. In: Metal Ions in Biological Systems. Sigel, HA (Ed.), Marcel Dekker, Inc., NY, USA (1997) 30:109-129.
28. UHLIN U, EKLUND H: The ten-suranded β/α barrel in ribonucleotide reductase protein R1. J. Mol. Biol. (1996) 262:358-369.
29. ELIASSON R, FONTECAVE M, JORNVALL H et al.: The anaerobic ribonucleoside triphosphate reductase from Escherichia coli ribonucleotide reductase requires S-adenosylmethionine as a cofactor. Proc. Natl. Acad. Sci. USA (1990) 87:3314-3318.
30. PADOVANI D, THOMAS F, TRAUTWEIN AX et al.: Activation of class III ribonucleotide reductase from Escherichia coli. The electron transfer from the iron-sulfur center to S-adenosylmethionine. Biochemistry (2001) 40:6713-6719.
31. TORRENTS E, ELIASSON R, WOLPHNER H et al.: The anaerobic ribonucleotide reductase from Lactococcus lactis. Interactions between the two proteins NRDD and NRDG. J. Biol. Chem. (2001) 276:33488-33494.
32. SUN XY, ELIAISSON R, PONTIS F et al.: Generation of the glycyl radical of the anaerobic Escherichia coli ribonucleotide reductase requires a specific activating enzyme. J. Biol. Chem. 270:2443-2446.
33. MULLIEZ E, OLLAGNIER S, FONTECAVE M et al.: Formate is the hydrogen donor for the anaerobic ribonucleotide reductase from Escherichia coli. Proc. Natl. Acad. Soc. USA (1995) 92:8759-8762.
34. SUN X, OLLAGNIER S, SCHMIDT PP et al.: The free radical of the anaerobic ribonucleotide reductase from Escherichia coli is at glycine 681. J. Biol. Chem. (1996) 271:6827-6831.
35. ABERG A, NORLUND P, EKLUND H: Unusual clustering of carboxyl side chains in the core of iron-free ribonucleotide reductase. Nature (1993) 361:276-278.
36. LOGAN DT, DEMARE F, PERSSON BO et al.: Crystal structures of two self-hydroxylating ribonucleotide reductase protein R2 mutants: structural basis for the oxygen-insertion step of hydroxylation reactions catalyzed by diiron proteins. Biochemistry (1998) 37:10798-10807.
37. EKBERG M, POTSCH S, SADIN E et al.: Preserved catalytic site in an engineered ribonucletide reductase R2 protein with a nonphysiological radical transfer pathway. The importance of hydrogen bond connections between the participating residues. J. Biol. Chem. (1998) 273:21003-21008.
38. GEREZ C, ELLEINGARD K, KAUPPI B et al.: Reactivity of the tyrosyl radical of Escherichia coli ribonucleotide reductase - control by the protein. Eur. J. Biochem. (1997) 249:401-407.
39. LARSSON A, CLIMENT I, NORDLUND P et al.: Structural and functional characterization of two mutated R2 proteins of Escherichia coli ribonucleotide reductase. EMBO. J. (1996) 5:2037-2040.
40. TONG W, BURDI D, RIGGS-GELASCO P et al.: Characterization of Y122F R2 of Escherichia coli ribonucleotide reductase by time-resolved physical biochemical methods and X-ray crystallography. Biochemistry (1998) 37:5840-5848.
41. KAUPPI B, NIELSEN BA, RAMASWAMY S et al.: The three dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site then Escherichia coli. J. Mol. Biol. (1996) 262:706-720.
42. ERIKSSON M, JORDAN A, EKLUND H: Structure of Salmonella typhimurium nrdF ribonucleotide reductase in its oxidized and reduced form. Biochemistry (1998) 37:13359-13369.
43. HUQUE Y. Radical generation and transfer in ribonucleotide reductase. Department of Molecular Biology and Functional Genomics, Stockholm University, Stockholm, Sweden (2001).
44. UHLIN U, EKLUND H: Structure of ribonucleotide reductase protein R1. Nature (1994) 370:533-539.
45. CARLSON J, FUCHS JA, MESSING J: Primary structure of the Escherichia coli ribonucleotide reductase operon. Proc. Natl. Acad. Soc. USA (1984) 81:4294-4297.
46. BOLLINGER JM JR, EDMONDSON DE, HUYNH BH et al.: Mechanism of assembly of the tyrosyl radical-dinuclear iron cluster cofactor of ribonucleotide reductase. Science (1991) 253:292-298.
47. SAHLIN M, GRASLUND A, PETERSSON L et al.: Reduced forms of the iron-containing small subunit of ribonucleotide reductase from Escherichia coli. Biochemistry (1989) 28:2618-2625.
48. SJOBERG BM, REICHARD P, GRASLUND A et al.: The tyrosine free radical in ribonucleotide reductase from Escherichia coli. J. Biol. Chem. (1978) 253:6863-6865.
49. LOZANO G, ELLEDGE SJ: p53 sends nucleotides to repair DNA. Nature (2000) 404:24-25.
50. NAKANO K, BALINT E, ASHCROFT M et al.: A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene (2000) 19:4283-4289.
51. TANAKA H, ARAKAWA H, YAMAGUCHI T et al.: A ribonucleotide reductase gene involved in p53-dependent cell-cycle checkpoint for DNA damage. Nature (2000) 404:42-49.
52. CHABES A, THELANDER L: Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. (2000) 275:17747-17753.
53. SANTOCANALE C, DIFFLEY JF: A Mecl- and Rad53-dependent checkpoint controls late-firing origins of DNA replication. Nature (2000) 395:615-618.
54. SZEKERES T, FRITZER-SZEKERES M, ELFORD HL: The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit. Rev. Clin. Lab. Sci. (1997) 34:503-528.
55. ELFORD HL: Effect of ribonucleotide reductase. Biochem. Biophys. Res. Common. (1968) 33:129-135.
56. KRAKOFF IH: Clinical and pharmacological effects of hydroxyurea. In: Antineoplastic and Immunosuppressive Agents. Part II. Sartorelli AC and Jones DG (Eds), Springer-Verlag, Berlin (1975):789-792.
57. FONTECAVE M, ELIASSON R, REICHARD P: Enzymatic regulation of the radical content of the small subunit of Escherichia coli ribonucleotide reductase involving reduction of its redox centers. J. Biol. Chem. (1989) 264:9164-9170.
58. SAHLIN M, SJOBERG BM, BACKES G et al.: Activation of the iron-containing small subunit of ribonucleotide reductase from Escherichia coli. Biochemistry (1990) 28:2618-2625.
59. DONEHOWER RC: An overview of the clinical experience with hydroxymea. Semin. Oncol. (1992) 19:11-19.
60. KENNEDY BJ: The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin. Oncol. (1992) 19:21-26.
61. STEHMAN FB: Concurrent chemoradiation in carcinoma of the uterine cervix. Semin. Oncol. (1992) 19:88-91.
62. RANDI ML, RUZZON E, LUZZATTO G et al.: Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica (2005) 90:261-262.
63. FONTECAVE M: Ribonucleotide reductases and radical reactions. Cell Mol. Sci. (1998) 54:684-695.
64. FINCH RA, LIU M, GRILL SP et al.: Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. (1992) 59:983-991.
65. ELFORD HL, VAN'T RIET B: The inhibition of nucleoside diphosphates reductase by hydroxybenzodroxamic acid derivatives. In: Inbibitors of Ribonucleoside Diphosphate Reductase Activity. Cory JG, Cory AH (Eds), (1989):217-233.
66. YOUNG CW, SCHOCHETMAN G, HODAS S et al.: Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. Cancer Res. (1967) 27:535-540.
67. VAN'T RIET B, WAMPLER GL, ELFORD HL: Synthesis of hydroxy- and amino substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J. Med. Chem. (1979) 22:589-592.
68. ELFORD HL, WAMPLER GL, VAN'T REIT B: New ribonucleotide reduccase inhibitors with antineoplastic activity. Cancer Res. (1979) 39:844-851.
69. ELFORD HL, VAN'T RIET B, WAMPLER GL et al.: Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Adv. Enz. Reg. (1981) 19:151-168.
70. ELFORD HL, ELFORD RM, WAMPLER G L et al.: New cancer chemotherapeutic agents that inhibit ribonucleotide reductase. In: New Approaches to the Design of Antineoplastic Agents. Bardos T, Kalman T (Eds), Elsevier Science, NY, USA (1982):151-168.
71. BROWN NC, ELIASSON R, REICHARD P et al.: Spectrum and iron content of protein B2 from ribonucleotide diphosphates reductase. Eur. J. Biochem. (1969) 9:512-518.
72. ATKIN CL, THELANDER L, REICHARD P et al.: Iron and free radical in ribonucleotide reductase. Exchange of iron and Mossbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme. J. Biol. Chem. (1973) 248:7464-7472.
73. PETERSSON L, GRASLUND A, EHRENBERG A et al.: The iron center in ribonucleotide reductase from Escherichia coli. J. Biol. Chem. (1980) 225:6706-6712.
74. VENKER P, HERZMANN H: Radikalangereigenschaften einiger Phenole. Naturewissenschaften (1960) 47:133-134.
75. RAUKO P, ROMANOVA D, MIADOKOVA E et al.: DNA-protective activity of new ribonucleotide reductase inhibitors. Anticancer Res. (1997) 17:3427-3440.
76. KJOLLER-LARSEN I, SJOBERG BM, THELANDER L: Characterization of the active site of ribonucleotide reductase of Escherichia coli bacteriophage T4 and mammalian cells by inhibition studies with hydroxyurea analogues. Eur. J. Biochem. (1982) 125:75-81.
77. STUBBE JA, ACKLES D: On the mechanism of ribonucleotide diphosphate reductase from Escherichia coli: Evidence for 3′-C-H bond cleavage. J. Biol. Chem. (1980) 225:8027-8030.
78. THELANDER L, GRASLUND A: Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J. Biol. Chem. (1983) 258:4063-4066.
79. CARMICHAEL J, CANTWELL BM, MANNIX KA: A Phase I and pharmacokinetic study of didox administered by 36-hr infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br. J. Cancer (1990) 61:447-450.
80. VEALE D, CARMICHAEL J, CANTWELL BM: A Phase I and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br. J. Cancer (1988) 58:70-72.
81. RUBENS RD, KAYE SB, SOUKOP M: Phase II trial of didox in advanced breast cancer. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br. J. Cancer (1991) 64:1187-1188.
82. KRISTEN NL, RICCIO ES: The evaluation of didox in the Salmonella-Escherichia coli/microsome plate incorporation assay. SRI International. Final Report, commissioned by the National Institute of Allergy and Infectious Disease (NIAID), NIH, Dr Charles Litterst, Program Officer. SRI International, 333 Ravenswood Ave, Menlo Park, CA (2002) report on file.
83. INAYAT MS, CHENDIL D, MOHIUDDIN M et al.: Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated resistance in prostate cancer cell line, PC-3. Cancer Biol. Ther. (2002) 5:539-545.
84. BARRE-SINOUSI F, CHERMANN JC, REY F et al.: Isolation of a T-lymphotrophic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868-871.
85. GOODENOW M, HUET T, SAURIN W et al.: HIV-1 isolates are rapidly evolving quasi-species: evidence for viral mixtures and preferred nucleotide substations. J. Acq. Imm. Defic. Syndr. (1989) 2:344-352.
86. LIFSON JD, FEINBERG MB, REYES GR et al.: Induction of CD4 dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 323:725-728.
87. SHAFER RW, WINTERS MA, PLAMER S et al.: Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Inn. Med. (1988) 128:1515-1518.
88. VIGOUROUX C, GHARAHANIAN S, SALHI Y et al.: Adverse metabolic disorders during highly accive antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. (1999) 25:383-393.
89. DORNADULA G, ZHANG H, VAN ULTERT B et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. (1999) 282:1627-1632.
90. O'BRIEN WA, ZACH JA, CHEN IS: Molecular pathogenesis of HIV-1. AIDS (1990) 4:S41-S48.
91. BALZARINI J: Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors. Pharmacol. Ther. (2000) 87:175-187.
92. BALARINI J, LEE CK, HERDEWIJIN P et al.: Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. (1991) 266:21509-21514.
93. JOHNS DG, GAO WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem. Pharmacol. (1998) 55:1551-1556.
94. LORI F, MALYKH A, CARA A et al.: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science (1994) 266:801-805.
95. BIANCHI V, PONTIS E, REICHARD P: Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. (1986) 34:16037-16042.
96. SLABAUGH MB, HOWELL ML, WANG Y et al.: Deoxyadenosine reverses hydroxyurea inhibition of vaccine virus growth. J. Virol. (1991) 65:2290-2298.
97. GAO WY, JOHNS DG, CHOKEKUCHAI S et al.: Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1995) 92:8333-8337.
98. GAO WY, MITSUYA H, DRISCOLL JS et al.: Enhancement by hydroxyurea of the anti-human immunodeficiency virus Type 1 potency of 2′-β-fluoro-2′,3′-dideoxyadenosine in peripheral blood mononuclear cells. Biochem. Pharmacol. (1995) 50:274-276.
99. PALMER S, SHAFER RW, MERIGAN TC: Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. (1999) 43:2046-2050.
100. BIRON F, PONCEAU B, BOUHOUR D et al.: Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-patients. J. Acquir. Immune Defic. Syndr. (2000) 25:329-336.
101. RUTSCHMANN OT, OPRAVIL M, ITEN A et al.: Long-term hydroxyurea in combination with didanosine and stuvadine for the treatment of HIV-1 infection. Swiss Cohort Study. AIDS (2000) 14:2145-2151.
102. LORI F: Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS (1999) 13:1433-1442.
103. MASERATI R: Hydroxyurea in the treatment of HIV-1 infection. J. Biol. Regul. Homest. Agents (1999) 13:181-185.
104. VILLANI P, MASERATI R, REGAZZI MB et al.: Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus Type I. J. Clin. Pharmacol. (1996) 36:117-121.
105. LORI F, KELLY LM, FOLI A et al.: Safety of hydroxyurea in the treatment of HIV infeccion. Expert Opin. Drug Saf. (2004) 3:279-288.
106. LORI F, POLLARD R, SHALIT P et al.: A low hydroxyurea (600 mg daily) is found optimal in a randomized, controlled trial (RIGHT 702) AIDS research and human retroviruses. in press.
107. MURPHY R, KATLAMA C, AUTRAN B et al.: The effects of hydroxyurea or placebo combined with efavirenz, didanosine and stavudine in treatment naive and experienced patients: preliminary 24-week results from the 3D study. XIII International AIDS Conference, Durban, South Africa, WeOrB603 (2000).
108. USSERY MA, KUNDER SC, GOLDERG G et al.: In vitro antiretroviral activity of ribonucleotide reductase inhibitors hydroxyurea, didox and trimidox in the HIV-infected HuPBMC SCID model and the Rauscher murine leukemia virus (RmuLV) model: mono-and combination therapy. In: Program. Abstract of the International Conference on Antimitocrobial Agents Chemotherapy. (1996) Abstract no. 112.
109. MAYHEW CN, PHILLIPS JD, GREENBERG RN et al.: Effective use of ribonucleotide reductase inhibitors (didox and timidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in marine acquired immunodeficiency syndrome (MAIDS). Cell. Mol. Biol. (1999) 43:1019-1029.
110. MAYHEW CN, MAMPURU LJ, CHENDIL D et al.: Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox; novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antivir. Res. (2002) 56:167-181.
111. MAYHEW CN, PHILLIPS JD, GREENBERG RN et al.: In vivo and in vitro comparison of the short-term hematopoietic toxicity - hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential HIV-1 activity. Stem Cells (1999) 17:1019-1029.
112. SUMPTER LR, INAYAT MS, YOST EE et al.: In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors abacavir: suppression of retrovirus-induced immunodeficiency disease. Antivir. Res. (2004) 62:111-120.
113. MAYHEW CN, SUMPTER LN, INAYAT MS et al.: Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease. Antivir. Res. (2005) 65:13-22.
114. MAYHEW CN, PHILLIPS JD, CIBULL ML et al.: Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverse late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea. Antivir. Chem. Chemother. (2002) 13:305-314.